Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Aug 1;5(8):e2228008.
doi: 10.1001/jamanetworkopen.2022.28008.

Incubation Period of COVID-19 Caused by Unique SARS-CoV-2 Strains: A Systematic Review and Meta-analysis

Affiliations
Meta-Analysis

Incubation Period of COVID-19 Caused by Unique SARS-CoV-2 Strains: A Systematic Review and Meta-analysis

Yu Wu et al. JAMA Netw Open. .

Erratum in

  • Error in Discussion.
    [No authors listed] [No authors listed] JAMA Netw Open. 2022 Sep 1;5(9):e2235424. doi: 10.1001/jamanetworkopen.2022.35424. JAMA Netw Open. 2022. PMID: 36112381 Free PMC article. No abstract available.

Abstract

Importance: Several studies were conducted to estimate the average incubation period of COVID-19; however, the incubation period of COVID-19 caused by different SARS-CoV-2 variants is not well described.

Objective: To systematically assess the incubation period of COVID-19 and the incubation periods of COVID-19 caused by different SARS-CoV-2 variants in published studies.

Data sources: PubMed, EMBASE, and ScienceDirect were searched between December 1, 2019, and February 10, 2022.

Study selection: Original studies of the incubation period of COVID-19, defined as the time from infection to the onset of signs and symptoms.

Data extraction and synthesis: Following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline, 3 reviewers independently extracted the data from the eligible studies in March 2022. The parameters, or sufficient information to facilitate calculation of those values, were derived from random-effects meta-analysis.

Main outcomes and measures: The mean estimate of the incubation period and different SARS-CoV-2 strains.

Results: A total of 142 studies with 8112 patients were included. The pooled incubation period was 6.57 days (95% CI, 6.26-6.88) and ranged from 1.80 to 18.87 days. The incubation period of COVID-19 caused by the Alpha, Beta, Delta, and Omicron variants were reported in 1 study (with 6374 patients), 1 study (10 patients), 6 studies (2368 patients) and 5 studies (829 patients), respectively. The mean incubation period of COVID-19 was 5.00 days (95% CI, 4.94-5.06 days) for cases caused by the Alpha variant, 4.50 days (95% CI, 1.83-7.17 days) for the Beta variant, 4.41 days (95% CI, 3.76-5.05 days) for the Delta variant, and 3.42 days (95% CI, 2.88-3.96 days) for the Omicron variant. The mean incubation was 7.43 days (95% CI, 5.75-9.11 days) among older patients (ie, aged over 60 years old), 8.82 days (95% CI, 8.19-9.45 days) among infected children (ages 18 years or younger), 6.99 days (95% CI, 6.07-7.92 days) among patients with nonsevere illness, and 6.69 days (95% CI, 4.53-8.85 days) among patients with severe illness.

Conclusions and relevance: The findings of this study suggest that SARS-CoV-2 has evolved and mutated continuously throughout the COVID-19 pandemic, producing variants with different enhanced transmission and virulence. Identifying the incubation period of different variants is a key factor in determining the isolation period.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.
Figure 1.. Study Flow Diagram
Figure 2.
Figure 2.. Forest Plot for Studies of Incubation Period of COVID-19 Caused by Different Variants
Figure 3.
Figure 3.. Incubation Period for COVID-19 in Older Patients and Infected Children
Infectious strains were original strains.
Figure 4.
Figure 4.. Incubation Period for COVID-19 in Patients With Severe and Nonsevere Illness
Infectious strains were original strains.

References

    1. Guan W-J, Ni Z-Y, Hu Y, et al. ; China Medical Treatment Expert Group for Covid-19 . Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720. doi:10.1056/NEJMoa2002032 - DOI - PMC - PubMed
    1. World Health Organization . Coronavirus (COVID-19) Dashboard. 2022; https://covid19.who.int/.
    1. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;323(18):1824-1836. doi:10.1001/jama.2020.6019 - DOI - PubMed
    1. Gostic K, Gomez AC, Mummah RO, Kucharski AJ, Lloyd-Smith JO. Estimated effectiveness of symptom and risk screening to prevent the spread of COVID-19. Elife. 2020;9:9. doi:10.7554/eLife.55570 - DOI - PMC - PubMed
    1. Tawe Ngi AM, Johnston S, Albayat SS, et al. . Pre-symptomatic and asymptomatic transmission of COVID-19: Implications for control measures in Qatar. Qatar Med J. 2021;2021(3):59-59. - PMC - PubMed

Publication types

Supplementary concepts